{
  "id": "5c6df86b7c78d69471000045",
  "type": "yesno",
  "question": "Is baricitinib effective for rheumatoid arthritis?",
  "ideal_answer": "Yes, baricitinib is effective treatment of rheumatoid arthritis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28097393",
    "http://www.ncbi.nlm.nih.gov/pubmed/28440680",
    "http://www.ncbi.nlm.nih.gov/pubmed/24818516",
    "http://www.ncbi.nlm.nih.gov/pubmed/30058112",
    "http://www.ncbi.nlm.nih.gov/pubmed/29500799",
    "http://www.ncbi.nlm.nih.gov/pubmed/29687421",
    "http://www.ncbi.nlm.nih.gov/pubmed/29134891",
    "http://www.ncbi.nlm.nih.gov/pubmed/30191390",
    "http://www.ncbi.nlm.nih.gov/pubmed/28290136",
    "http://www.ncbi.nlm.nih.gov/pubmed/28199814",
    "http://www.ncbi.nlm.nih.gov/pubmed/27427830",
    "http://www.ncbi.nlm.nih.gov/pubmed/30219772",
    "http://www.ncbi.nlm.nih.gov/pubmed/28811354",
    "http://www.ncbi.nlm.nih.gov/pubmed/30006916",
    "http://www.ncbi.nlm.nih.gov/pubmed/29415145",
    "http://www.ncbi.nlm.nih.gov/pubmed/30183607"
  ],
  "snippets": [
    {
      "text": "CONCLUSION: Baricitinib 2\u2009mg and 4\u2009mg administered once daily, in combination with DMARD, were efficacious interventions for active RA that had no significant risk of TEAE development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28097393",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: The efficacy and safety profile of baricitinib was maintained during long-term treatment of Japanese patients with RA and background methotrexate therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28440680",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: In a phase IIb study in RA, the safety and tolerability profile of baricitinib, up to 128 weeks, remained consistent with earlier observations, without unexpected late signals. Clinical improvements seen in the 24-week blinded period were maintained during the OLE.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28811354",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: Data for baricitinib, with/without methotrexate, in Japanese subpopulations across all stages of the RA treatment continuum accord with the efficacy/safety profile in overall study populations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29134891",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion: Baricitinib demonstrated a consistent, beneficial treatment effect in bDMARD-refractory patients across subgroups based on baseline characteristics and prior bDMARD use.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29415145",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Baricitinib is effective in treatment of RA, and did not appear to have significant safety concerns during the first 6\u00a0months of treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30006916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE\nBaricitinib is an orally administered inhibitor of JAK1 and JAK2 that has been shown to be effective in treating rheumatoid arthritis (RA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30058112",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "EXPERT OPINION\nJAK inhibitors are effective in the treatment of rheumatoid arthritis as evidenced by several inhibitors enabling the majority of treated patients to achieve ACR20 responses, with baricitinib and INCB-039110 both effective when administered once daily.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE\nBaricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30219772",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two different Janus kinase (JAK) inhibitors-baricitinib and tofacitinib-are effective and licensed in active rheumatoid arthritis (RA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29500799",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Baricitinib for the treatment of rheumatoid arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27427830",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "OBJECTIVES\nOral targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs), including the Janus kinase inhibitors tofacitinib and baricitinib, are the latest addition to the therapeutic options for rheumatoid arthritis (RA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30183607",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Baricitinib (Olumiant\u2122) is an orally-administered, small-molecule, janus-associated kinase (JAK) inhibitor developed by Eli Lilly and Incyte Corporation for the treatment of rheumatoid arthritis (RA), atopic dermatitis and systemic lupus erythematosus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28290136",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "EXPERT OPINION JAK inhibitors are effective in the treatment of rheumatoid arthritis as evidenced by several inhibitors enabling the majority of treated patients to achieve ACR20 responses, with baricitinib and INCB-039110 both effective when administered once daily.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tofacitinib 10\u202fmg\u202f+\u2009methotrexate (MTX) and baricitinib 4\u202fmg\u202f+\u2009MTX were among the most effective treatments for active RA with an inadequate DMARD or biologic response, followed by baricitinib 2\u202fmg\u202f+\u2009MTX, tofacitinib 5\u202fmg\u202f+\u2009MTX, and adalimumab\u202f+\u2009MTX.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30191390",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE Baricitinib is an orally administered inhibitor of JAK1 and JAK2 that has been shown to be effective in treating rheumatoid arthritis (RA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30058112",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS In patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28199814",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thus, once-daily baricitinib, as monotherapy or in combination with methotrexate, is an effective and generally well tolerated emerging treatment for patients with moderate to severe active RA who have responded inadequately to or are intolerant of \u2265\u00a01 DMARD, and extends the options available for this population.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29687421",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES Oral targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs), including the Janus kinase inhibitors tofacitinib and baricitinib, are the latest addition to the therapeutic options for rheumatoid arthritis (RA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30183607",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Five phase 3 trials of Baricitinib, a JAK1 and JAK2 inhibitor, have been performed and showed high clinical efficacy in patients with active RA and na\u00efve to sDMARDs or an inadequate response to sDMARDs, MTX or bDMARDs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27427830",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "It is also reported that safety was tolerable within the limited study period.<br><b>AREAS COVERED</b>: We here review the recent progress in the development of baricitinib and its potential for the treatment of RA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27427830",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<b>OBJECTIVE</b>: Baricitinib is an orally administered inhibitor of JAK1 and JAK2 that has been shown to be effective in treating rheumatoid arthritis (RA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30058112",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In February 2017, baricitinib was approved in the EU, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28290136",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28199814",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In pivotal multinational trials, once-daily baricitinib 4\u00a0mg, with/without methotrexate (\u00b1\u00a0another csDMARD), improved the signs and symptoms of RA, disease activity and physical function in DMARD-naive patients and in patients with an inadequate response to methotrexate, csDMARDs or TNF inhibitors; baricitinib treatment also slowed structural joint damage in DMARD-naive patients and in those with an inadequate response to methotrexate and csDMARDs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29687421",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Five phase 3 trials of Baricitinib, a JAK1 and JAK2 inhibitor, have been performed and showed high clinical efficacy in patients with active RA and na\u00efve to sDMARDs or an inadequate response to sDMARDs, MTX or bDMARDs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27427830",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}